Decision-making, Experience, and Confidence In Determining Genomic Evaluation:

The DECIDE Survey

• Genomic testing for PCA can encompass tumor tissue tests, plasma circulating tumor DNA (ctDNA) tests, and germline tests.

• Genomic testing can have significant variability in marker/variants tests, comprehensiveness of the test, variant reporting, and clinical application.

• To enhance the translational impact of the PRECISION Registry, the study team developed the DECIDE Survey to collect information regarding self-confidence, knowledge, experience, and decision-making regarding prostate cancer genomic testing.

• We invite clinicians, scientists, researchers, etc. to take this survey to have comprehensive results applicable across disciplines impacting PCA precision medicine.

• This survey takes approximately 10-15 minutes to complete.

• Informed by results from the DECIDE Survey, our goal is to develop tools to help facilitate the use and interpretation of genomic tests for clinicians, scientists, and researchers to enhance patient care.